Literature DB >> 14972569

The L polymerase protein of parainfluenza virus 3 forms an oligomer and can interact with the heterologous Sendai virus L, P and C proteins.

Sherin Smallwood1, Sue A Moyer.   

Abstract

We recently showed that the L protein of Sendai virus is present as an oligomer in the active P-L polymerase complex [Smallwood et al., Virology 304 (2002) 235]. We now demonstrate using two different epitope tags that the L protein of a second respirovirus, human parainfluenza type 3 virus (PIV3), also forms an L-L complex. L oligomerization requires the coexpression of the differentially epitope tagged L proteins. By exploiting a series of C-terminal truncations the L-L binding site maps to the N-terminal half of L. There is some complex formation between the heterologous PIV3 and Sendai L and P proteins; however, the heterologous L protein does not function in transcription of either the PIV3 or Sendai template. The PIV3 C protein binds PIV3 L and inhibits RNA synthesis in vitro and in vivo. Significant homology exists between the C proteins of PIV3 and Sendai and complex formation occurs between the PIV3 and Sendai heterologous C and L proteins. In addition, the heterologous C proteins can inhibit transcription at approximately 50% of the level of the homologous protein. These data suggest that while the C proteins may be functionally somewhat interchangeable, the L and P proteins are specific for each virus.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14972569     DOI: 10.1016/j.virol.2003.09.045

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  25 in total

1.  Domain structure of Lassa virus L protein.

Authors:  Linda Brunotte; Michaela Lelke; Meike Hass; Katja Kleinsteuber; Beate Becker-Ziaja; Stephan Günther
Journal:  J Virol       Date:  2010-10-27       Impact factor: 5.103

2.  Genetic and biochemical evidence for an oligomeric structure of the functional L polymerase of the prototypic arenavirus lymphocytic choriomeningitis virus.

Authors:  Ana B Sánchez; Juan C de la Torre
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

Review 3.  Polymerases of paramyxoviruses and pneumoviruses.

Authors:  Rachel Fearns; Richard K Plemper
Journal:  Virus Res       Date:  2017-01-16       Impact factor: 3.303

4.  Independent structural domains in paramyxovirus polymerase protein.

Authors:  Melanie Dochow; Stefanie A Krumm; James E Crowe; Martin L Moore; Richard K Plemper
Journal:  J Biol Chem       Date:  2012-01-03       Impact factor: 5.157

5.  Regulation of Viral RNA Synthesis by the V Protein of Parainfluenza Virus 5.

Authors:  Yang Yang; James Zengel; Minghao Sun; Katrina Sleeman; Khalid Amine Timani; Jason Aligo; Paul Rota; Jianguo Wu; Biao He
Journal:  J Virol       Date:  2015-09-16       Impact factor: 5.103

6.  The L-VP35 and L-L interaction domains reside in the amino terminus of the Ebola virus L protein and are potential targets for antivirals.

Authors:  Martina Trunschke; Dominik Conrad; Sven Enterlein; Judith Olejnik; Kristina Brauburger; Elke Mühlberger
Journal:  Virology       Date:  2013-04-11       Impact factor: 3.616

7.  Respiratory syncytial virus polymerase can initiate transcription from position 3 of the leader promoter.

Authors:  Chadene Z Tremaglio; Sarah L Noton; Laure R Deflubé; Rachel Fearns
Journal:  J Virol       Date:  2013-01-02       Impact factor: 5.103

8.  Human parainfluenza virus type 2 V protein inhibits genome replication by binding to the L protein: possible role in promoting viral fitness.

Authors:  Machiko Nishio; Junpei Ohtsuka; Masato Tsurudome; Tetsuya Nosaka; Daniel Kolakofsky
Journal:  J Virol       Date:  2008-04-16       Impact factor: 5.103

9.  Rift valley fever virus L protein forms a biologically active oligomer.

Authors:  Aya Zamoto-Niikura; Kaori Terasaki; Tetsuro Ikegami; C J Peters; Shinji Makino
Journal:  J Virol       Date:  2009-10-07       Impact factor: 5.103

Review 10.  Reverse genetics approaches to combat pathogenic arenaviruses.

Authors:  Juan C de la Torre
Journal:  Antiviral Res       Date:  2008-09-07       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.